Innovation Pharmaceuticals Inc (IPIX)

[sunspotter]

“Cubicin (Daptomycin), has generated over $1 billion in annual sales and is an antibiotic that Brilacidin has performed comparably to, both in the literature and in clinical trials, where Brilacidin went head-to-head with it in Phase 2”

Ehrlich forget to mention that brilacidin caused twice as many adverse events as daptomycin and had six serious adverse events against none for daptomycin (although that latter finding was apparently one of those one in several million to one random occurrences that just happen when the principal investigator is also a company employee).